

Solid Tumors

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Preliminary Efficacy of Atezolizumab (Anti-Programmed Death-Ligand 1 [PD-L1] Antibody) in Pediatric and Young Adult Participants With Solid Tumors

Trial Status
Terminated

Trial Runs In
11 Countries

Trial Identifier
NCT02541604 2014-004697-41
GO29664

The source of the below information is the publicly available website ClinicalTrials.gov. It has been summarised and edited into simpler language.

Trial Summary:

This early phase, multicenter, open-label, single-arm study evaluated the safety, tolerability, pharmacokinetics, immunogenicity, and preliminary efficacy of atezolizumab in pediatric and young adult participants with solid tumors for which prior treatment was proven to be ineffective.

Hoffmann-La Roche
Sponsor

Phase 1/Phase 2
Phase

NCT02541604 2014-004697-41 GO29664
Trial Identifiers

Eligibility Criteria:

Gender
All

Age
≤ 30 Years

Healthy Volunteers
No